This was the stock's third consecutive day of gains.

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

周一，摩根大通对纳斯达克上市的Vertex Pharmaceuticals Incorporated（股票代码：VRTX）的目标价做出了微调，从503.00美元下调至500.00美元。该公司维持了对该股票的增持评级。根据 InvestingPro 数据，该股票目前交易价格为397.27美元，过去一周下跌了15%。此次调整是在Alyf trek获得提前批准并符合市场预期后做出的。

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

12月19日，专注于罕见病治疗的药品开发公司Vertex ...

摩根大通：将Vertex Pharmaceuticals的目标价从503美元下调至500美元，但维持“增持”评级。(格隆汇) ...

周一，Truist Securities调整了市值1,010亿美元的知名生物技术公司Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的目标价。该股票在过去一周下跌超过15%，承受了巨大压力。该公司分析师将目标价从之前的550美元下调至460美元，同时维持对该股票的买入评级。根据 InvestingPro ...

导读：12月9日消息，Bluebird、Vertex/CRISPR的基因疗法，与美国CMS（美国联邦医疗保险和医疗补助服务中心）正式达成“按结果付费”的协议，将于明年1月正式推出新的支付模式。01 昂贵的基因疗法自2012年第一款基因疗法在欧盟获批上 ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

圣诞老人即将出发，将礼物送到世界各地的小朋友手中。不过，圣诞老人每年也会给投资者送上一份大礼，也就是所谓的“圣诞上涨行情”（Santa Claus Rally）。具体到医疗行业，艾伯维（AbbVie，ABBV）、诺和诺德（Novo ...